Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a Chinese biopharmaceutical company, has announced the enrollment of the first patient in a Phase III clinical study for its investigational bispecific antibody-drug conjugate (ADC), BL-B01D1. This in-house developed molecule is designed to target locally advanced, recurrent, or metastatic HR+/HER2- breast cancer.
The EGFR×HER3 bispecific ADC, BL-B01D1, has received multiple clinical trial approvals and is under investigation for a variety of indications, including advanced gastric cancer, advanced small-cell lung cancer, advanced triple-negative breast cancer, advanced urothelial carcinoma, advanced esophageal squamous cell carcinoma, advanced head and neck squamous cell carcinoma, and advanced nasopharyngeal carcinoma. This molecule gained significant attention with an $8.4 billion licensing deal secured with US pharmaceutical giant Bristol-Myers Squibb at the end of 2023.- Flcube.com
